Consistent with these, our data showed that the expression of TNF-α, MCP-1, IL-6, IL-1β, and MPO activity was significantly increased in pancreas and colon of the model group, while formononetin treatment downregulated their levels, indicating formononetin ameliorated AP and associated colonic inflammation. This evidence concerns the gene IL6 and colitis.